Your browser doesn't support javascript.
loading
Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.
Lou, Xiaotong; Hu, Yuanyuan; Zhang, Hong; Liu, Jia; Zhao, Yin.
Affiliation
  • Lou X; Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Hu Y; Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Zhang H; Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Liu J; Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. jialiu1207@hust.edu.cn.
  • Zhao Y; Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhaoyin85@hust.edu.cn.
J Nanobiotechnology ; 19(1): 436, 2021 Dec 20.
Article in En | MEDLINE | ID: mdl-34930292
BACKGROUND: Oxidative stress contributes to retina ganglion cells (RGCs) loss in variety of ocular diseases, including ocular trauma, ocular vein occlusion, and glaucoma. Scavenging the excessed reactive oxygen species (ROS) in retinal neurovascular unit could be beneficial to RGCs survival. In this study, a polydopamine (PDA)-based nanoplatform is developed to protect RGCs. RESULTS: The PDA nanoparticles efficiently eliminate multi-types of ROS, protect endothelia and neuronal cells from oxidative damage, and inhibit microglia activation in retinas. In an optic nerve crush (ONC) model, single intravitreal injection of PDA nanoparticles could significantly attenuate RGCs loss via eliminating ROS in retinas, reducing the inflammatory response and maintaining barrier function of retinal vascular endothelia. Comparative transcriptome analysis of the retina implied that PDA nanoparticles improve RGCs survival probably by altering the expression of genes involved in inflammation and ROS production. Importantly, as a versatile drug carrier, PDA nanoparticles could deliver brimonidine (a neuroprotection drug) to synergistically attenuate RGCs loss and promote axon regeneration, thus restore visual function. CONCLUSIONS: The PDA nanoparticle-based therapeutic nanoplatform displayed excellent performance in ROS elimination, providing a promising probability for treating retinal degeneration diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymers / Retinal Degeneration / Optic Nerve Injuries / Nanoparticles / Indoles Limits: Animals / Humans / Male Language: En Journal: J Nanobiotechnology Year: 2021 Document type: Article Affiliation country: China Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymers / Retinal Degeneration / Optic Nerve Injuries / Nanoparticles / Indoles Limits: Animals / Humans / Male Language: En Journal: J Nanobiotechnology Year: 2021 Document type: Article Affiliation country: China Country of publication: United kingdom